Reuben, A. ., Spencer, C. ., Prieto, P. ., , Reddy, S. ., Miller, J. ., … Wargo, J. . Genomic and immune heterogeneity are associated with differential responses to therapy in melanoma. NPJ Genomic Medicine, 2. https://doi.org/10.1038/s41525-017-0013-8 (Original work published 2017)

, Spencer, C. ., Nezi, L. ., Reuben, A. ., Andrews, M. ., Karpinets, T. ., … Wargo, J. . (2018). Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients. Science (New York, N.Y.), 359(6371), 97-103. https://doi.org/10.1126/science.aan4236 (Original work published 2018)

Khouri, I. ., Curbelo, F. ., Turturro, F. ., Jabbour, E. ., Milton, D. ., RL, B. . , Jr, … Sharma, P. . (2018). Ipilimumab plus Lenalidomide after Allogeneic and Autologous Stem Cell Transplantation for Patients with Lymphoid Malignancies. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research, 24(5), 1011-1018. https://doi.org/10.1158/1078-0432.CCR-17-2777 (Original work published 2018)

Ariyan, C. ., Brady, M. ., Siegelbaum, R. ., Hu, J. ., Bello, D. ., Rand, J. ., … Allison, J. . (2018). Robust Antitumor Responses Result from Local Chemotherapy and CTLA-4 Blockade. Cancer Immunology Research, 6(2), 189-200. https://doi.org/10.1158/2326-6066.CIR-17-0356

Amaria, R. ., Prieto, P. ., Tetzlaff, M. ., Reuben, A. ., Andrews, M. ., Ross, M. ., … Wargo, J. . (2018). Neoadjuvant plus adjuvant dabrafenib and trametinib versus standard of care in patients with high-risk, surgically resectable melanoma: a single-centre, open-label, randomised, phase 2 trial. The Lancet. Oncology, 19(2), 181-193. https://doi.org/10.1016/S1470-2045(18)30015-9

Daver, N. ., Boddu, P. ., Garcia-Manero, G. ., Yadav, S. ., Sharma, P. ., Allison, J. ., & Kantarjian, H. . (2018). Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia, 32(5), 1094-1105. https://doi.org/10.1038/s41375-018-0070-8

Goswami, S. ., Apostolou, I. ., Zhang, J. ., Skepner, J. ., Anandhan, S. ., Zhang, X. ., … Sharma, P. . (2018). Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy. The Journal of Clinical Investigation. https://doi.org/10.1172/JCI99760 (Original work published 2018)

Sharma, A. ., Subudhi, S. ., Blando, J. ., Scutti, J. ., Vence, L. ., Wargo, J. ., … Sharma, P. . (2018). Anti-CTLA-4 immunotherapy does not deplete FOXP3+ regulatory T cells (Tregs) in human cancers. Clinical Cancer Research : An Official Journal of the American Association for Cancer Research. https://doi.org/10.1158/1078-0432.CCR-18-0762 (Original work published 2018)